Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. The company also develops Psilocybin, which is in Phase 1 clinical study for treating methamphetamine use disorder; and Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases. Revive Therapeutics Ltd. is based in Toronto, Canada. Show more
Location: The Canadian Venture Building, Toronto, ON, M5C 1P1, Canada | Website: https://revivethera.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare
Market Cap
4.406M
52 Wk Range
$0.01 - $0.03
Previous Close
$0.01
Open
$0.01
Volume
11,476
Day Range
$0.01 - $0.01
Enterprise Value
4.517M
Cash
0.00
Avg Qtr Burn
N/A
Insider Ownership
1.51%
Institutional Own.
0.00%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Bucillamine Details COVID-19 | Phase 3 Update |
